Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

ICAAC Clinical Trials Review Available

October 18, 2002

ICAAC, the Inter-Science Conference on Antimicrobial Agents and Chemotherapy, was held this year in San Diego, September 27-30. This annual conference focuses mainly on the development of new antibiotics and antivirals. On October 11 HIVandHepatitis.com published a review of the HIV clinical trial presentations at ICAAC, by Charles Hicks, M.D.; it is available at: www.hivandhepatitis.com/2002conf/iccac2002/pages/35.html.

Some of the topics:

  • Atazanavir, an experimental protease inhibitor being developed by Bristol-Myers Squibb, was compared in a large international trial with efavirenz (brand name Sustiva -- or Stocrin in some countries);

  • 3TC (Epivir) was successfully dosed for once-daily use;

    Advertisement

  • Coviracil, an experimental nucleoside reverse-transcriptase inhibitor, was compared with d4T; and

  • For certain advanced patients, a combination of amprenavir (Agenerase) and lopinavir plus ritonavir (Kaletra), with some extra ritonavir (Norvir) added to overcome an interaction that would reduce the levels the other two drugs, appeared to work well.

All of these trials showed promising results that may improve HIV treatment in the future.


ISSN # 1052-4207

Copyright 2002 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.




  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News.
 

Tools
 

Advertisement